Arrien Pharmaceuticals is a "FIELDS" technology driven biopharmaceutical company focused on discovery and development of innovative and effective drug candidates for the treatment of human cancers. The company currently has three drug candidates for oncology and two other programs in development for non-oncology indications.
ARN-6039 completed its Phase 1 clinical trials and was partnered with Boston Pharmaceuticals in 2017.
ARN-3261 is a SIK2 inhibitor in development, competed its IND enabling studies and the anticipated clinical Phase 1a/1b trial to begin in Q1, 2019 in ovarian and other solid tumor patients.
Company's FIELDS (Fields Ion Pairs/Hydrogen Bonds Electrostatics Linear Free-Energy Desolvation/Polar Scoring/Clustering) technology is an In-House proprietary ~4600 plus unique, novel fragments & scaffolds with proprietary RO3 criteria coupled with empirical Ki/Kd/IC50/EC50 data lead to the creation of training set of druggable clinical/disease relevant protein targets is a key behind the FIELDS technology. Our FIELDS approach rapidly aid our scientific team in selecting candidate ready compounds rapidly in to pre-clinical studies.